NUTX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010, for iGambit, Inc. (Note: The input metadata referenced "Nutex Health Inc.", but the filing text explicitly identifies the registrant as iGambit, Inc.). The Company is a smaller reporting company focused on technology markets. Its primary operating subsidiary, Gotham Innovation Lab Inc., provides media technology services to the real estate industry. Additionally, the Company receives revenue share payments from Digi-Data Corporation related to a 2006 asset sale (discontinued operations).

Key Financial Metrics

Cash Flow: Net cash used by operating activities was $(449,631) for Q1 2010, compared to $(84,982) in Q1 2009. This was offset by net cash provided by investing activities of $344,760, primarily from discontinued operations.

Material Changes vs. Prior Period

• Revenue Generation: Continuing operations generated $167,342 in revenue in Q1 2010, compared to zero in Q1 2009, driven by the Gotham subsidiary.
• Expense Surge: General and administrative expenses increased significantly to $429,567 from $42,626 in the prior year. This increase was driven by officer salaries, professional fees for SEC registration, and Gotham operational costs.
• Net Income Decline: Despite revenue growth, Net Income decreased to $156,186 from $309,270. This was due to the operating loss in continuing operations and a slight decrease in income from discontinued operations ($344,993 vs. $353,115).
• Liquidity: Cash balances decreased by $67,792 during the quarter, though total cash remains higher than the prior year-end due to the timing of discontinued operation payments.

Outlook, Risks, and Management Commentary

• Revenue Dependency: Management highlights a critical risk: the Company's primary source of income is contingency payments from Digi-Data Corporation (discontinued operations). If Digi-Data fails to generate sufficient revenue or ceases operations, the Company's ability to continue as a going concern is in doubt.
• Discontinued Operations Timeline: The revenue share agreement with Digi-Data is set to end on February 28, 2011. The Company expects payments to continue growing until then based on Digi-Data's expansion.
• Subsidiary Performance: Gotham Innovation Lab is not currently cash flow positive. It generated a net loss of $(98,655) for the quarter. Management anticipates Gotham's business will grow throughout 2010 but notes that expansion may require additional capital.
• Capital Requirements: The Company anticipates raising capital in private markets to fund Gotham's expansion or potential acquisitions. There is no guarantee of obtaining funds on acceptable terms.
• Goodwill Impairment: Goodwill of $185,000 related to the Jekyll acquisition is not amortized but subject to annual impairment testing. Management states it is too early to evaluate impairment as Gotham's core business is expected to commence later in 2010.

Investor Verification Checklist

• Digi-Data Revenue Health: Verify the financial stability and revenue growth of Digi-Data Corporation, as iGambit's profitability relies heavily on these contingent payments.
• Gotham Cash Burn: Monitor the cash burn rate of the Gotham subsidiary and its ability to achieve profitability before the Digi-Data revenue stream expires in early 2011.
• Capital Raising Plans: Assess the Company's ability to raise additional capital in the private markets to fund operations and potential acquisitions.
• Related Party Transactions: Review the $37,079 note payable to a related party and the $17,000 notes receivable from stockholders for terms and repayment status.
• Goodwill Valuation: Watch for future impairment charges on the $185,000 goodwill asset if Gotham fails to meet projected operating results.